🔍

SIGACHI - Sigachi Indust.

📊 NSE: SIGACHI 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:22

📢 Recent Corporate Announcements

Sigachi Industries Credit Rating Downgraded to CARE BBB; Outlook Remains Negative

🔴 NEGATIVE ⭐ 8/10

REGULATORY 📅 25 Feb 2026, 05:38 PM

CARE Ratings has downgraded Sigachi Industries' long-term facilities and NCDs from BBB+ to BBB following a sharp decline in operating margins to 5.25% in Q3FY26. The company reported a significant net loss of ₹90.46 crore for the quarter, impacted by ₹116.35 crore in exceptional provisions related to a fatal fire incident at its Hyderabad plant. Liquidity is currently strained due to delayed insurance claims of ₹51 crore and increased working capital requirements. Additionally, the promoter group has seen a decline in shareholding due to the invocation of pledged shares, signaling financial leverage concerns.

Long-term credit rating downgraded to CARE BBB from CARE BBB+; remains on Rating Watch with Negative Implications.
Operating margins collapsed to 5.25% in Q3FY26 compared to 24.89% in Q3FY25 due to higher costs and lower yields.
Reported a net loss of ₹90.46 crore in Q3FY26 after accounting for ₹116.35 crore in fire-related compensation and asset losses.
Promoter shareholding decreased recently due to multiple instances of pledged share invocations and open-market sales.
Company is raising ₹125 crore through NCDs to fund a ₹493 crore expansion plan and bridge liquidity gaps.

💡 Investors should remain cautious as the downgrade reflects deteriorating financial health, high leverage, and uncertainty regarding the ongoing fire investigation. It is advisable to wait for signs of margin recovery and successful insurance claim realization before making further commitments.

Sigachi Q3 FY26: Revenue at ₹117.2 Cr, EBITDA Margin Drops to 4.6% Post-Fire Impact

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 20 Feb 2026, 02:21 PM

Sigachi Industries reported a total operating income of INR 117.2 crores for Q3 FY26, but faced significant margin pressure with EBITDA falling to INR 5.7 crores (4.6% margin). The company recorded a marginal net loss of INR 0.02 crores, primarily due to the operational impact and cost redistribution following a fire accident at its Hyderabad unit. Management remains optimistic about recovery, targeting a total cellulose-based excipient capacity of 30,000 MTPA by Q3 FY27. Despite current headwinds, demand for Microcrystalline Cellulose (MCC) remains strong with exports accounting for 62% of production.

Reported Q3 FY26 operating income of INR 117.2 crores with a marginal net loss of INR 0.02 crores.
EBITDA margin compressed to 4.6% due to overhead redistribution and higher logistics costs post-Hyderabad fire.
MCC capacity expansion of 12,000 MTPA at Dahej is on track for commissioning in Q3 FY27, taking total capacity to 30,000 MTPA.
Current cellulose-based excipient capacity stands at 18,000 MTPA with 62% of production exported.
O&M and API segments contributed INR 13.35 crores and INR 14.13 crores respectively to the quarterly revenue.

💡 Investors should monitor the progress of the Dahej expansion and the stabilization of margins as the company moves past the one-time costs associated with the Hyderabad incident. The stock may remain under pressure until EBITDA margins return to the historical 20% plus range.

Sigachi Industries Releases Q3 FY 2025-26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 14 Feb 2026, 06:09 PM

Sigachi Industries Limited has made the audio recording of its Q3 FY 2025-26 earnings conference call available to the public. This filing is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors can access the recording on the company's official website to hear management's detailed commentary on the quarter's financial performance. This provides transparency regarding the company's operational updates and future growth strategies for the period ending December 2025.

Audio recording of the Q3 FY 2025-26 earnings call is now live on the company website.
Compliance with SEBI (LODR) Regulations for timely disclosure of investor meets.
Provides access to management's discussion on quarterly financial results and outlook.
The recording is hosted at www.sigachi.com for all stakeholders.

💡 Investors should listen to the recording to understand management's guidance on margins and capacity utilization. No immediate action is required as this is a routine regulatory disclosure.

Sigachi Industries Q3 Net Profit Slumps to ₹0.20 Cr; Revenue Down 16% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 14 Feb 2026, 03:49 PM

Sigachi Industries reported a weak Q3 FY26 with consolidated revenue declining 16% YoY to ₹117.21 crore. Net profit attributable to shareholders plummeted to ₹0.20 crore from ₹21.35 crore in the same period last year, reflecting severe margin pressure. The company's performance continues to be overshadowed by a massive ₹117.08 crore exceptional loss recorded in the nine-month period due to a major fire at its Hyderabad plant. While revenue grew 6% on a sequential (QoQ) basis, the bottom line remains strained as insurance claims for the fire damage are yet to be recognized in the financial statements.

Consolidated Revenue from operations fell 15.9% YoY to ₹117.21 crore in Q3 FY26.
Net Profit attributable to shareholders crashed to ₹0.20 crore compared to ₹21.35 crore in Q3 FY25.
Total 9-month consolidated loss stands at ₹90.45 crore, primarily due to a ₹117.08 crore exceptional item from a fire accident.
Employee benefit expenses increased significantly to ₹23.68 crore from ₹19.46 crore YoY.
Insurance claims for the fire accident at the Hyderabad plant are pending and have not been accounted for as income yet.

💡 Investors should exercise caution as the company faces significant operational headwinds and profit erosion following the Hyderabad plant fire. The stock's recovery depends on the successful settlement of insurance claims and the scaling up of its new API and MCC expansion projects.

Sigachi Industries Schedules Q3 FY26 Earnings Call for February 14, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 09 Feb 2026, 04:38 PM

Sigachi Industries Limited has announced its earnings conference call to discuss the unaudited financial results for Q3 and 9M FY 2025-26. The call is scheduled for Saturday, February 14, 2026, at 4:30 PM IST. Senior management, including MD & CEO Amit Raj Sinha and CFO O. Subbarami Reddy, will be present to address investor queries. This routine event provides a platform for stakeholders to understand the company's recent operational performance and future guidance.

Earnings call for Q3 & 9M FY26 scheduled for February 14, 2026, at 4:30 PM IST
Management representation includes MD & CEO Amit Raj Sinha and CFO O. Subbarami Reddy
Universal dial-in numbers provided are +91 22 6280 1557 and +91 22 7115 8383
The call is being hosted by Go India Advisors

💡 Investors should participate in the call or review the transcript to gain insights into the company's margin profile and progress on any ongoing expansion projects.

Sigachi Industries MD & CEO Amit Raj Sinha Granted Bail in 2025 Incident Case

🔵 WATCH ⭐ 7/10

LEGAL 📅 04 Feb 2026, 11:20 AM

The Hon’ble High Court of Telangana has granted bail to Sigachi Industries' MD & CEO, Amit Raj Sinha, in relation to legal proceedings from an industrial incident on June 30, 2025. This incident involved fatalities and injuries, leading to a period of significant legal and operational strain for the company. While the CEO's release may restore some leadership stability, the company continues to face ongoing judicial processes and investigations. Sigachi has committed to enhancing safety protocols across its units to prevent future occurrences.

Telangana High Court granted bail to MD & CEO Amit Raj Sinha on February 4, 2026.
Legal matter pertains to a tragic industrial incident that occurred on June 30, 2025.
Company is cooperating with investigating authorities and the judicial process.
Management is focusing on strengthening safety systems and practices across all operations.

💡 Investors should monitor the final outcome of the legal proceedings and any potential financial penalties or regulatory impact on the company's manufacturing licenses. While the CEO's bail is a short-term relief for management stability, the long-term focus should be on the company's improved safety compliance.

Sigachi Achieves R&D Milestone in Cystic Fibrosis APIs; ₹250 Cr Annual Revenue Potential

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 21 Jan 2026, 11:09 AM

Sigachi Industries has successfully advanced a new combination of Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs), including Vanzacaftor, Tezacaftor, and Deutivacaftor. This development targets a global CF therapeutics market valued at over USD 10 billion, characterized by high entry barriers and strong pricing resilience. The company estimates an annual revenue potential of approximately ₹250 crore from this portfolio, with commercialization expected to commence in Q4 FY 2026–27. Long-term revenue visibility is supported by innovator patent protection for Vanzacaftor extending until 2039.

Successful development of high-value CF API combination: Vanzacaftor, Tezacaftor, and Deutivacaftor
Estimated annual revenue potential of ~₹250 crore starting from Q4 FY 2026–27
Targets a global cystic fibrosis therapeutics market exceeding USD 10 billion
Innovator patent protection for Vanzacaftor extends until 2039, ensuring long-term opportunity
Strategic shift towards complex specialty APIs with high entry barriers and limited competition

💡 Investors should view this as a significant move towards higher-margin specialty APIs, though the financial impact is slated for late FY27. Monitor for updates on strategic collaborations with formulation innovators which will be crucial for commercializing this pipeline.

Sigachi Industries Reports Nil Demat/Remat Requests for Quarter Ended December 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 03:48 PM

Sigachi Industries Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company and its Registrar and Share Transfer Agent, Bigshare Services Private Limited, confirmed that no requests for dematerialization or rematerialization were received during the quarter ended December 31, 2025. This is because 100% of the company's shares are already held in dematerialized form. This filing is a standard regulatory requirement and indicates smooth administrative operations regarding shareholding.

Regulation 74(5) compliance confirmed for the quarter ended December 31, 2025
100% of the company's shares are currently held in dematerialized form
Zero requests for dematerialization or rematerialization received during the three-month period
Confirmation provided by Registrar and Share Transfer Agent (RTA) Bigshare Services Private Limited

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's core business performance and upcoming financial results.

Sigachi Industries Appoints Atul Dhavle as Chief People Officer to Drive Global Growth

🟢 POSITIVE ⭐ 4/10

MANAGEMENT 📅 05 Jan 2026, 09:51 AM

Sigachi Industries has appointed Mr. Atul Dhavle as its Chief People Officer (CPO) effective January 3, 2026, to strengthen its organizational capability. Mr. Dhavle brings nearly 30 years of experience in human capital leadership, having previously served as CHRO at Granules India Limited. His background includes senior leadership roles at major firms like Dr. Reddy’s, Bharat Forge, and Mahindra. This strategic hire is aimed at supporting Sigachi's expansion across 65+ countries and its 5 manufacturing facilities by aligning talent development with business priorities.

Mr. Atul Dhavle appointed as Chief People Officer effective January 3, 2026
Brings nearly 30 years of experience from top-tier firms including Granules India, Dr. Reddy’s, and Mahindra
Tasked with aligning human capital strategy with long-term growth across 5 multilocational facilities
Educational background includes a PG Certificate from XLRI Jamshedpur and a B.E. in Production Engineering
Appointment aims to support the company's global footprint spanning 65+ countries

💡 Investors should view this as a positive step towards institutionalizing the company's growth strategy and professionalizing management. No immediate action is required, but this strengthens the leadership depth for the company's next phase of expansion.

Sigachi Industries to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 10:24 AM

Sigachi Industries Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 01, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial result declaration. The closure pertains to the unaudited standalone and consolidated financial results for the quarter ending December 31, 2025. The trading window will reopen 48 hours after the results are officially disseminated to the stock exchanges.

Trading window closure starts from Thursday, January 01, 2026.
Closure is linked to the upcoming unaudited financial results for the quarter ended December 31, 2025.
Restriction applies to all designated persons and their immediate relatives as per SEBI norms.
The window will remain closed until 48 hours after the public announcement of the financial results.

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should monitor for the upcoming board meeting date when Q3 results will be discussed.

Sigachi MD & CEO Amit Raj Sinha Remanded Over June 2025 Fire Incident Investigation

🔴 NEGATIVE ⭐ 9/10

MANAGEMENT 📅 28 Dec 2025, 02:58 PM

Sigachi Industries' MD & CEO, Amit Raj Sinha, was remanded on December 27, 2025, in connection with an ongoing investigation into a fire incident at the company's Hyderabad unit that occurred on June 30, 2025. To ensure business continuity, the company has appointed Deputy Group CEO Lijo Stephen Chacko to oversee operations in the interim. This development introduces significant leadership uncertainty and potential legal risks for the company following the industrial accident earlier in the year. Investors should be wary of the impact on corporate governance and potential regulatory repercussions.

MD & CEO Amit Raj Sinha remanded on December 27, 2025, regarding the Pashamylaram unit fire.
The fire incident at the Hyderabad facility occurred on June 30, 2025, and is under active investigation.
Deputy Group CEO Lijo Stephen Chacko has been tasked with overseeing interim operations.
The company maintains that day-to-day activities and operational continuity are being managed.

💡 Investors should adopt a cautious approach as the detention of a top executive can lead to leadership instability and reputational risks. Monitor further legal updates and the company's ability to maintain operational performance under interim management.

Sigachi Industries Credit Rating Downgraded to CARE BBB+; Negative Watch Continues

🔴 NEGATIVE ⭐ 8/10

REGULATORY 📅 26 Dec 2025, 12:24 PM

CARE Ratings has downgraded Sigachi Industries' long-term rating from CARE A- to CARE BBB+ following a devastating fire at its Hyderabad facility in June 2025. The incident destroyed 30% of the company's capacity (6,400 MTPA), leading to a significant H1FY26 net loss of ₹90.44 crore due to ₹116.35 crore in exceptional provisions for compensation and asset loss. To manage liquidity and fund a ₹493 crore capex plan, the company is raising ₹125 crore through NCDs while awaiting ₹51 crore in insurance claims. The rating remains on 'Rating Watch with Negative Implications' pending the outcome of government investigations and final compensation payouts.

Long-term bank facilities downgraded to CARE BBB+ from CARE A- and Short-term to CARE A3+ from CARE A2.
Exceptional provision of ₹116.35 crore created in H1FY26 for fire-related compensation and asset loss.
Installed capacity dropped from 21,700 MTPA to 15,300 MTPA after the Hyderabad plant destruction.
Company plans to raise ₹125 crore via NCDs to bridge liquidity gaps and fund a ₹493 crore multi-year capex plan.
Insurance claim of ₹51 crore for plant and machinery loss expected in tranches by Q4FY26 or Q1FY27.

💡 Investors should exercise caution as the 'Negative Watch' indicates potential for further downgrades depending on legal outcomes and insurance recovery timelines. Monitor the company's ability to successfully ramp up Gujarat capacity to 18,000 MTPA to offset production losses.

View All SIGACHI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, the MCC segment contributed INR 66.4 Cr (60% of revenue, down from 81% YoY), the API segment recorded INR 18.41 Cr (17% of revenue, up from 7% YoY), and O&M services contributed INR 13.17 Cr (12% of revenue, up from 8% YoY). Overall revenue for Q2 FY26 was INR 110.5 Cr, a 13.80% decrease from INR 128.2 Cr in Q2 FY25.

Geographic Revenue Split

Not explicitly disclosed in percentages, but the company has a significant export presence through Sigachi US Inc. and is actively pursuing 9 Certificate of Suitability filings with the European Directorate of Quality and Medicine to expand in regulated European markets.

Profitability Margins

Gross margin for Q2 FY26 was 35.96%, down from 37.75% in Q2 FY25. Net Profit (PAT) margin stood at 9.59% (INR 10.5 Cr) in Q2 FY26 compared to 16.81% (INR 21.0 Cr) in Q2 FY25, representing a 722 bps decline due to operational disruptions.

EBITDA Margin

EBITDA margin plummeted to 6.78% (INR 7.5 Cr) in Q2 FY26 from 21.38% (INR 29.3 Cr) in Q2 FY25, a contraction of 1460 bps. This was primarily driven by the Pashamylaram unit fire incident which increased operational costs and disrupted high-margin MCC production.

Capital Expenditure

The company is investing INR 90 Cr in a new Croscarmellose Sodium (CCS) facility, with INR 32.30 Cr already earmarked in fixed deposits. Additionally, it is fast-tracking a 12,000 MTPA expansion at Dahej SEZ to reach a total capacity of 33,700 MTPA.

Credit Rating & Borrowing

CARE Ratings reaffirmed 'CARE A-; Stable' for long-term facilities (INR 75.38 Cr) and 'CARE A2' for short-term facilities (INR 51.75 Cr). The overall gearing ratio stood at 0.40x as of September 30, 2024, with interest coverage at 7.27x.

⚙️ Operational Drivers

Raw Materials

Refined wood pulp is the primary raw material, accounting for nearly 100% of the material requirement for MCC production.

Import Sources

100% of refined wood pulp is imported from Switzerland, USA, Canada, and South Africa due to lack of domestic availability of the required grade.

Key Suppliers

Not disclosed by specific company names, but the company maintains a concentrated supplier base with long-term established relationships.

Capacity Expansion

Current installed capacity is 21,700 MTPA (increased from 14,500 MTPA in FY24). A planned expansion of 12,000 MTPA at Dahej SEZ is underway, targeting a total capacity of 33,700 MTPA. The CCS facility is expected to commence operations in October 2026.

Raw Material Costs

Raw material costs are a significant portion of the total expenses which were INR 103.0 Cr in Q2 FY26. Procurement is 100% import-dependent, making the company sensitive to global pulp prices and forex fluctuations.

Manufacturing Efficiency

The Dahej expansion is expected to generate peak revenue of INR 250 Cr at full utilization. The company is currently deprioritizing low-throughput SKUs to optimize resources during the recovery phase.

Logistics & Distribution

Distribution costs were impacted by the 'prompt relocation' of production from Hyderabad to Gujarat (Dahej and Jhagadia) to maintain supply consistency for global customers.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Growth is driven by expanding MCC capacity to 33,700 MTPA, commercializing the new CCS product line by 2026, and increasing API revenue through the newly operational R&D center in Hyderabad. The company is also targeting high-value regulated markets in Europe with 9 active CEP filings.

Products & Services

Microcrystalline Cellulose (MCC) in 60 grades, Active Pharmaceutical Ingredients (APIs), Croscarmellose Sodium (CCS), and Operations & Maintenance (O&M) services for pharma plants.

Brand Portfolio

Sigachi, Trimax Bio Sciences (80% owned subsidiary).

New Products/Services

Croscarmellose Sodium (CCS) and new API molecules developed at the Hyderabad R&D center; CCS facility has a peak revenue potential linked to the INR 90 Cr investment.

Market Expansion

Expanding presence in regulated markets (Europe/USA) and scaling the API portfolio through the Raichur facility (Trimax) which has a 100 KL capacity.

Market Share & Ranking

Leading global manufacturer of pharmaceutical excipients; specific global market share percentage not disclosed.

Strategic Alliances

Acquired 80% stake in Trimax Bio Sciences Private Limited for INR 100 Cr to enter the API manufacturing segment.

🌍 External Factors

Industry Trends

The excipient industry is shifting toward high-purity, multi-functional grades. Sigachi is positioning itself as a fully integrated pharma company by moving from excipients (MCC) into APIs and specialized chemicals (CCS).

Competitive Landscape

Competes with global excipient manufacturers but maintains an edge in regulated markets due to quality certifications and a diverse product range.

Competitive Moat

Moat is built on 60 distinct grades of MCC (15 to 250 microns) and high regulatory barriers in 'regulated markets' where Chinese players are less competitive. This is sustainable due to the long lead times for pharmaceutical ingredient approvals.

Macro Economic Sensitivity

Highly sensitive to global trade cycles and pharmaceutical demand; revenue grew 33% in FY24 during a period of healthy demand.

Consumer Behavior

Increasing demand for nutraceuticals and high-quality pharmaceutical excipients is driving volume growth in the MCC segment.

Geopolitical Risks

Exposure to trade barriers in wood pulp exporting countries (Switzerland, USA, Canada) and regulatory changes in European pharmaceutical markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent EDQM (European Directorate of Quality and Medicine) standards and USFDA requirements for API and excipient manufacturing.

Environmental Compliance

Received environmental clearance for the CCS facility in April 2025.

Taxation Policy Impact

Tax expense for Q2 FY26 was INR 3.1 Cr on a PBT of INR 7.4 Cr (effective rate ~41% for the quarter, impacted by exceptional items).

Legal Contingencies

The company is processing insurance claims for the Pashamylaram unit fire incident (June 2025) which fully covers structural damage, inventory, and 90 days of production loss.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for the full restoration of the Pashamylaram unit and the successful ramp-up of the Dahej expansion to offset current margin pressure (EBITDA down 74% QoQ).